eScholarship
metadata only
A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma
Osteosarcoma (OSA) represents the most common primary bone tumor in humans and pet dogs. Little progress has been made with regard to viable treatment options in the past three decades and patients presenting with metastatic disease continue to have a poor prognosis. Recent mouse studies have sugges
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Next-generation osteosarcoma models for precision medicine.#375265
- Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors#291662
- Orthopaedic Oncology in Contemporary Practice: A Comprehensive Review of Primary Bone Tumours, Metastatic Pathways, and Evolving Surgical Techniques.#354595
- SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression#291640
- Hydrogel-Based Immunomodulatory Strategies for Infected Bone Defects Regeneration: Remodeling the Osteoimmune Microenvironment and Future Perspectives.#368016
Record · ID 1038704
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive